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Background: Adult skeletal muscle regeneration is a highly orchestrated process involving the activation and
proliferation of satellite cells, an adult skeletal muscle stem cell. Activated satellite cells generate a transient
amplifying progenitor pool of myoblasts that commit to differentiation and fuse into multinucleated myotubes.
During regeneration, canonical Wnt signalling is activated and has been implicated in regulating myogenic lineage
progression and terminal differentiation.
Methods: Here, we have undertaken a gene expression analysis of committed satellite cell-derived myoblasts to
examine their ability to respond to canonical Wnt/β-catenin signalling.
Results: We found that activation of canonical Wnt signalling induces follistatin expression in myoblasts and promotes
myoblast fusion in a follistatin-dependent manner. In growth conditions, canonical Wnt/β-catenin signalling prime
myoblasts for myogenic differentiation by stimulating myogenin and follistatin expression. We further found that
myogenin binds elements in the follistatin promoter and thus acts downstream of myogenin during differentiation.
Finally, ectopic activation of canonical Wnt signalling in vivo promoted premature differentiation during muscle
regeneration following acute injury.
Conclusions: Together, these data reveal a novel mechanism by which myogenin mediates the canonical Wnt/
β-catenin-dependent activation of follistatin and induction of the myogenic differentiation process.
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The growth, maintenance, and regeneration of skeletal
muscle is attributed to the satellite cell; a mitotically
quiescent cell that resides between the basal lamina and
sarcolemma of the muscle fiber [1-3]. During muscle
regeneration, satellite cells activate, proliferate, and
differentiate into new myofibers or fuse to existing
myofibers. Skeletal muscle regeneration is a highly
orchestrated process contingent upon the proper expression
of the paired-box transcription factor Pax7, and the
basic helix-loop-helix (bHLH) myogenic regulatory
factors (MRFs); Myf5, MyoD, myogenin, and MRF4* Correspondence: mrudnicki@ohri.ca
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unless otherwise stated.[4]. Collectively, MRFs undergo heterodimerization
with the ubiquitously expressed E-protein family of
bHLH proteins that mediate the recognition of E-box
consensus sequences (CANNTG) found in the promoters
of many muscle-specific genes [5]. Myf5 and MyoD
function to specify myogenic identity in proliferating
myoblasts, whereas myogenin and MRF4 are upregulated
during differentiation to trigger the expression of myogenic
differentiation-specific genes [6].
Skeletal muscle regeneration is regulated through
mechanisms involving cellular interactions and extracellular
signalling pathways. The Wnt signalling pathway has
been shown to play a critical role in regulating various
developmental programs through embryonic development
and in the regulation of stem cell function in adult tissues
[7]. During skeletal muscle regeneration, multiple Wnt
signals are activated [8]. We have previously shown that
the symmetric expansion of satellite stem cells and theirhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Jones et al. Skeletal Muscle  (2015) 5:14 Page 2 of 11orientation along the axis of division is controlled by the
non-canonical Wnt/PCP-pathway [9]. Wnt7a-mediated
polarization of α7-integrin and the PCP core-component
molecule Vangl2, on opposite poles of the daughter cells,
allows both cells to maintain contact with the basal lamina
and thus preserve their orientation relative to the niche.
However, there are paradoxical roles for the canonical
Wnt/β-catenin pathway during adult skeletal muscle
regeneration. Evidence exists that suggests Wnt/β-catenin
signalling promotes the proliferation and self-renewal of
satellite cells, thus preventing myogenic differentiation
[10]. In contrast, other research suggests Wnt/β-catenin
signalling antagonizes Notch signalling leading to increased
terminal differentiation possibly in a BCL9-dependent
manner [11,12]. During muscle regeneration, Notch
signalling is activated and stimulates the proliferation
of satellite cells leading to the expansion of proliferating
myoblasts [13]. During differentiation, Wnt/β-catenin
signalling antagonizes the effects of Notch signalling, and
through reduced GSK3β levels, allows progression of
myogenic commitment and differentiation [11]. Among
others, we have previously shown that myogenic cells
stimulated with Wnt3a activate the canonical Wnt
pathway leading to nuclear stabilization of activated
β-catenin. In vivo, overexpression of Wnt3a in the
tibialis anterior (TA) muscle results in an increased
number of myofibers, which exhibit a dramatic reduction
in the cross-sectional area and reduced regenerative
efficiency. In vitro, canonical Wnt treatment of satellite
cell-derived myoblasts inhibits cellular proliferation, a
characteristic not observed by non-canonical Wnt
treatment [9]. In addition to modulating the satellite
cell compartment, canonical Wnt signalling has been
implicated in satellite cell-related transdifferentiation
and increasing myogenic potential [14,15].
To further investigate the role of canonical Wnt sig-
nalling in adult myogenesis, we analyzed the response of
satellite cell-derived myoblasts to Wnt/β-catenin sig-
nalling. We show that canonical Wnt signalling is associ-
ated with committed satellite cell differentiation potential
and control of follistatin expression. Investigation of the
role for a Wnt-follistatin pathway leads us to discover that
Wnt3a/β-catenin signalling controls the induction of
myogenic differentiation via the MyoD-dependent activa-
tion of myogenin expression. These findings suggest that
Wnt/β-catenin signalling controls multiple steps of
adult myogenesis by promoting premature myogenic
differentiation in a myogenin-dependent manner.
Methods
Cell culture and transfection
Primary myoblasts were isolated from the hind limbs of
4- to 6-week-old wild-type C57Bl/6J mice, as previously
described [16], and propagated on collagen-coated culturedishes in Ham’s F10 media supplemented with 20% fetal
bovine serum (FBS), 1% penicillin/streptomycin, and
2.5 ng/ml human recombinant bFGF. Myogenic differ-
entiation was induced by shifting to differentiation
media (DMEM supplemented with 5% horse serum).
Single myofibers were isolated from the extensor digitorum
longus (EDL) muscles and cultured in suspension in
DMEM supplemented with 15% FBS and 0.5% Chick
Embryo Extract (Accurate Chemical Co., Westbury, NY,
USA) as previously described [17]. For cell stimulation,
recombinant Wnt3a (20 ng/ml), Dickkopf-related protein
1 (Dkk1) (50 ng/ml), and follistatin (250 ng/ml) pro-
teins were added in the culture medium (R&D Systems,
Minneapolis, MN, USA). SiRNA transfections were
performed in growth media using Lipofectamine 2000
Reagent (Invitrogen, Waltham, MA, USA), as per
manufacturer’s instructions. siFollistatin and siMyogenin
duplexes were from Ambion (ID s66250, s70334) (Thermo
Fisher Scientific, Waltham, MA, USA) and used at the
final concentration of 2 nM each.
Animals
Care of animals is in accordance with institutional
guidelines as regulated by the Canadian Council of
Animal Care (CCAC). Protocols were approved by
Animal Research Ethics Board (AREB) at the University of
Ottawa and are reviewed on an annual basis. Eight- to
12-week-old wild-type C57Bl/6J mice were used in this
study. The TA muscle was injured by injection of
50 μl cardiotoxin (10 μM, Sigma, St. Louis, MO, USA).
(2′Z,3′E)-6-Bromoindirubin-3′-oxime (BIO) was recon-
stituted in DMSO at a concentration of 5 mM (B1686,
Sigma) combined with saline as vehicle and injected
directly into the TA muscle in a volume of 10 μl at a final
concentration of 1 μM.
Gene expression analyses
Affymetrix MoGene 1.0 ST chipsets (Santa Clara, CA,
USA) were RMA normalized [18] using the xps in
Bioconductor R package [19] with the Affymetrix pro-
vided MoGene-1_0-st-v1.r4 chip layout and scheme
files. The RMA normalized data was log2 transformed and
analyzed using the Significance Analysis of Microarrays
(SAM) [20] method as implemented in the Bioconductor
siggenes package [21]. Heat maps were generated by
GenePattern [22]. Gene ontology of expression data
was performed using the functional annotation module of
DAVID 6.7 [23,24].
Quantitative PCR
Total RNA was isolated using the RNeasy Kit and
subjected to on-column DNase digestion, as per manufac-
turer’s instructions (Qiagen, Venlo, Netherlands). cDNA
synthesis was performed using the Superscript III reverse
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SYBR Green quantitative polymerase chain reaction
(qPCR) was carried out as previously described [25].
Transcript levels were normalized to GAPDH transcript
levels. Relative fold change in expression was calculated
using the ΔΔCT method (CT values <30). PCR
primers were designed using the online Primer3 software
(http://primer3.wi.mit.edu) [26]. Primer sequences are
listed in Additional file 1: Table S1.
Western blot
Total protein was harvested in RIPA lysis buffer fortified
with protease inhibitors (Complete-Mini; Roche-Boehringer,
Ingelheim am Rhein, Germany), and protein concentration
was determined by Bradford assay (BioRad, Hercules, CA,
USA). Samples (20 μg) were subjected to SDS-PAGE and
electroblotted onto Immobilon-P membrane (Millipore,
Billerica, MA, USA). Membranes were blocked in 5% nonfat
milk in PBST, prior to sequential probing with primary anti-
body and HRP-conjugated secondary antibody in blocking
solution. ECL (Amersham-Pharmacia, Amersham, UK) with
BioMax XAR film (Kodak, Rochester, NY, USA) was used
to detect target proteins. Primary antibodies used for
detection are as follows: α-Pax7 (Developmental Studies
Hybridoma Bank, Iowa City, IA, USA), α-myogenin (F5D;
Developmental Studies Hybridoma Bank), α-follistatin
(Abcam, Cambridge, UK), and α-Tubulin (Sigma).
Secondary antibodies were HRP-conjugated anti-mouse
and anti-rabbit (1:5000; BioRad).
Immunocytochemistry
Adherent cell cultures were fixed with 4% PFA, perme-
abilized with 0.2% Triton-X in PBS, and incubated with
primary antibodies: myogenin (M-225) from Santa Cruz
(Dallas, TX, USA), α-MyHC (Developmental Studies
Hybridoma Bank), and α-Laminin (Sigma). Alexa-488 and
Alexa-555 conjugated secondary antibodies that matched
the primary antibodies were used at 1:1,000 in PBS
(Invitrogen). Nuclei were counterstained with DAPI
(Sigma-Aldrich). Images were obtained using an Axioplan2
microscope (Carl Zeiss, Oberkochen, Germany), a ×20 NA
0.75 plan Apochromat (ω/0.17; Carl Zeiss) objective, and a
digital Axiocam camera (Carl Zeiss). Digital images were
captured using Axiovision (Carl Zeiss) and were processed
with Photoshop (Adobe, San Jose, CA, USA).
ChIP analysis
Protein-DNA complexes were cross-linked with 1%
formaldehyde (Sigma) and sheared by sonication. Processing
of samples was performed as previously described [27];
2,000 μg of protein-DNA complexes were immunoprecipi-
tated with 4 to 5 μg of α-myogenin (Santa Cruz) or
control Rabbit IgG overnight, followed by wash con-
ditions and DNA elution performed according to thechromatin immunoprecipitation (ChIP) Assay Kit (Upstate
Biotechnology, Lake Placid, NY). The immunoprecipitated
DNA was subjected to real-time PCR, and results were nor-
malized using control locus representing DNA fragments
that were nonspecifically bound. Myogenin chromatin im-
munoprecipitation sequencing (ChIP-Seq) was performed
by chromatin tandem affinity purification, and data was
analyzed as described previously [28].
Statistical analysis
Three or more replicates were analyzed for each experiment
presented. Data is shown as standard error of the mean
(SEM), and results were assessed for statistical significance
by Student’s T-test. Differences were considered statistically
significant at the P < 0.05 level.
Results
Canonical Wnt signalling induces follistatin expression in
myoblasts
Multiple Wnt signals are active during muscle regeneration
[8]. To further investigate the role of canonical Wnt
signalling in adult myogenesis, we analyzed the response of
satellite cell-derived myoblasts to Wnt/β-catenin signalling
by genome-wide microarray expression analysis. Low-
passage primary myoblasts were treated with recombinant
Wnt3a, which we previously demonstrated activates the
canonical Wnt/β-catenin pathway in satellite cells [9], or
control bovine serum albumin (BSA) protein for 24 h
(Figure 1A). Wnt3a stimulation resulted in significant
expression changes in 401 genes relative to BSA control
(fold change >2, P value <0.05); 90 genes were upregulated,
while 311 genes were downregulated.
To investigate the global transcriptional effects of
Wnt3a treatment, we conducted an unbiased DAVID
analysis of our microarray data. Functional annotation
clustering of related gene ontology (GO) terms re-
vealed that Wnt3a stimulation strongly regulated cell
cycle, cell division, and the progression of mitosis
(Additional file 2: Figure S1). Heat maps depicting
fold changes for the top 20 regulated genes following
Wnt3a treatment relative to BSA-treated controls
were generated (Figure 1B). We validated a subset of
regulated genes by qPCR and observed upregulation
in the expression of the canonical Wnt-responsive
gene Axin2 (19-fold), TGFβ2 (approximately tenfold), and
Cxcl12 (14-fold) (Figure 1C). Strikingly, we observed that
expression of follistatin, a secreted glycoprotein that
antagonizes members of the TGF-β superfamily, was
increased by 15.3-fold following Wnt3a stimulation
(Figure 1C), independent of an effect on myostatin expres-
sion (Figure 1D). We observed a decrease in the expres-
sion of genes associated with the progression of mitosis
and cell proliferation E2F1 (approximately twofold),
Ki67 (sixfold), and cyclin E2 (fivefold) following Wnt3a
Figure 1 Follistatin expression is regulated by canonical Wnt/β-catenin signalling. (A) Schematic depicting the in vitro treatment of myoblasts
with rWnt3a. (B) Global heat map ratio representing the difference in gene expression patterns following treatment with recombinant Wnt3a
or control BSA protein. Red represents genes that increase in expression relative to the BSA-treated control, while blue represents a decrease.
(C) qPCR validation of a subset of genes upregulated following Wnt3a treatment relative to BSA control. Data are presented as the mean ± SEM
(n = 3, *P < 0.05, **P < 0.01), normalized to GAPDH and shown relative to BSA control. (D) qPCR validation of a subset of genes downregulated
following Wnt3a treatment relative to BSA control. Data are presented as the mean ± SEM (n = 3, *P < 0.05, **P < 0.01), normalized to GAPDH,
and shown relative to BSA control. (E) qPCR analysis of Pax7, follistatin, Axin2, and Myh2 expression levels in a myoblast differentiation time-course.
Pax7 expression is reduced, while Myh2 expression increases during differentiation. Follistatin expression is upregulated during the first 24 h of
differentiation in a similar fashion as the Wnt target Axin2. Data are presented as the mean ± SEM (n = 3), normalized to GAPDH. (F) qPCR analysis of
Axin2 and follistatin expression in myoblasts cultured in differentiation media for 24 h, following recombinant Wnt3a, Dkk1, or control BSA protein
treatments. Data are presented as the mean ± SEM (n = 3), normalized to GAPDH.
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stimulation Pax7 expression was reduced (approximately
twofold) while myogenin was increased (approximately
twofold), indicative of myogenic commitment (Figure 1C,D).
Following our global microarray analysis, we focused on
follistatin, given its strong upregulation following Wnt
treatment and its previously characterized role in pro-
moting differentiation and muscle hypertrophy [29-31].
To further study follistatin stimulation in response to
activation of Wnt/β-catenin signalling, we analyzed its
relative expression during a myoblast differentiation timecourse (Figure 1E). During myogenic differentiation,
Pax7 transcription diminishes while the expression of
differentiation markers (such as myosin heavy chain,
Myh2) become elevated. We observed that Axin2
expression was strongly increased within the first
24 h of differentiation, consistent with an increase in
Wnt/β-catenin signalling, and this was concomitant to
a tenfold increase in follistatin expression.
Given follistatin expression is upregulated following the
induction of differentiation, we next examined if the
modulation of Wnt/β-catenin signalling during myogenic
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expression. To this aim, we treated differentiating cells
with recombinant Wnt3a protein, the canonical Wnt
antagonist Dkk1, or BSA as a control. We observed
that while Wnt3a stimulation resulted in an increase in
follistatin and Axin2 expression levels, their expression
levels were reduced following Dkk1-mediated inhibition
of Wnt/β-catenin activity (Figure 1F). These observations
further suggest that the regulation of follistatin expression
following Wnt3a treatment is dependent on the canonical
Wnt signalling pathway.
Canonical Wnt signalling promotes myoblast fusion in a
follistatin-dependent manner
To determine if the induction of follistatin expression by
canonical Wnt signals was necessary for myogenic
differentiation, we conducted gain- and loss-of-function
experiments. We cultured single EDL myofibers in
floating conditions and assessed the proportion of
differentiating myogenin+ cells within clusters after
3 days in vitro (Figure 2A). We observed that treatment
of either Wnt3a or follistatin proteins after 24 h in
culture resulted in a 32% ± 5% increase in the proportion
of myogenin+ satellite cells, whereas a reduction in
myogenin+ satellite cells was observed following Dkk1
protein stimulation (43% ± 8%), or knockdown of follis-
tatin expression via siRNA (38% ± 8%) when compared
to controls (untreated cells or cells transfected with
non-silencing Scrambled siRNAs) (Figure 2B). Further,
we observed that either Wnt3a or follistatin treatment
resulted in larger myotubes with an increased number of
nuclei per myotube, while inhibition of Wnt/β-catenin
signalling via Dkk1 treatment and inhibition of follistatin
signalling via siRNA-mediated gene silencing limited
myogenic fusion, and led to the formation of short
myotubes (Figure 2C,D).
To validate that follistatin acts downstream of Wnt/
β-catenin signalling during myogenic differentiation, we
first determined the optimal concentration of siRNA
against follistatin for transfection in the presence of
Wnt3a to reduce follistatin expression to control levels
(transfected with non-silencing Scrambled siRNAs)
(Figure 2E, left). We next observed that in differentiating
myoblasts, the increase in fusion index induced by Wnt3a
is dependent on the increase in follistatin expression
(Figure 2E, right). Taken together, these observations
implicate follistatin as a canonical Wnt signalling tar-
get whose expression promotes differentiation-induced
myogenic fusion.
Canonical Wnt/β-catenin signalling primes myoblasts for
myogenic differentiation
A recent report demonstrated that myogenin expression
represses genes involved in cell cycle progression, andis sufficient to induce exit from the cell cycle [32].
Since we observed a major suppression of cell prolif-
eration genes following Wnt3a stimulation (Figure 1D,
Additional file 2: Figure S1), we sought to explore the
possible involvement of myogenin during Wnt/β-catenin
induced muscle differentiation. We first quantified the
relative expression levels of follistatin and myogenin in
growth conditions, where expression levels are low relative
to differentiation conditions (Figure 3A). Following Wnt
stimulation, we observed increased myogenin and follista-
tin and decreased Pax7 protein levels in growth conditions
relative to BSA controls (Figure 3B). While expressions of
myogenin and follistatin are induced during differenti-
ation, it was striking to observe that Wnt3a stimulation
upregulated their expression in growth conditions.
Previous data revealed that β-catenin directly interacts
with MRFs enhancing their ability to bind E-box regulator
elements and ultimately promoting muscle differentiation
[33]. More recent evidence demonstrates that β-catenin
can directly bind and activate cis elements of the MyoD
promoter [34]. In light of β-catenin’s ability to interact
with MyoD and myogenin and enhance their capacity to
activate downstream target genes, we examined a recently
unpublished data set comprising myogenin chromatin
immunoprecipitation coupled with massive parallel high-
throughput sequencing (ChIP-Seq), which allowed us to
identify a myogenin regulatory element upstream of the
follistatin promoter during differentiation. We identified a
conserved regulatory E-box element 30-kb upstream of
the follistatin gene locus that is occupied by myogenin
during early differentiation (Additional file 3: Figure S2,
unpublished data). Interestingly, a recent publication from
our lab identifies this element as being occupied during
proliferation not by myogenin but rather by the Snail-
HDAC1/2 repressive complex inhibiting myogenin
from accessing this E-box motif [28]. We further analyzed
the binding of myogenin on this regulatory element in
proliferating conditions following Wnt3a stimulation by
ChIP-PCR. Our results demonstrate an approximately
threefold enrichment of myogenin binding to this con-
served element following Wnt3a stimulation (Figure 3D).
Taken together, these observations link canonical Wnt
signalling to the expression of follistatin in a myogenin-
dependent manner.
Follistatin acts downstream of myogenin during
differentiation
To demonstrate that follistatin acts downstream of
myogenin expression, we first determined the optimal
concentration of siRNA against myogenin for trans-
fection in the presence of Wnt3a to reduce myogenin
expression similar to control levels (BSA treatment
transfected with non-silencing Scrambled siRNAs)
(Additional file 4: Figure S3). Wnt3a treatment and
Figure 2 Canonical Wnt/β-catenin signalling promotes myoblast fusion in a follistatin-dependent manner. (A) EDL single myofibers were cultured
in floating conditions for 3 days, and immunostained for Pax7 and myogenin expression. Shown is a typical myogenic cell cluster. (B) Percentage
of myogenin+ cells on myofibers following 24 h of recombinant Wnt3a, Dkk1, or control BSA protein treatments (left) and following 24 h recombinant
follistatin protein treatment, siRNAs against follistatin transfection, or control scrambled siRNAs transfection. (C) Myoblasts were cultured in
differentiation medium for 3 days in the presence of recombinant Wnt3a, Dkk1, follistatin, or control BSA proteins or transfected with siRNAs against
follistatin and immunostained for Myh2 expression. Scale bar 25 μM. (D) Quantification of the fusion index in myogenic cultures. Changes
are expressed as relative to the control (BSA treatment or siScr transfection). Data are presented as the mean ± SEM (n = 3, **P < 0.01).
(E) qPCR analysis of follistatin expression (left) and quantification of the fusion index (right) of myoblasts cultured in differentiation media for 24 h treated
with siScr and BSA, siScr and Wnt3a, or siFst and Wnt3a. Data are presented as the mean ± SEM (n = 3, *P < 0.05, **P < 0.01), normalized to GAPDH.
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reduction in follistatin expression in proliferating
myoblasts (Figure 3E). These results suggest that, in vitro,canonical Wnt stimulation of follistatin occurs in a
myogenin-dependent manner and leads to precocious
myogenic differentiation.
Figure 3 Wnt3a prime myoblasts for myogenic differentiation. (A) qPCR analysis of follistatin and myogenin expression levels in proliferating and
differentiating myoblasts. Data are presented as the mean ± SEM (n = 3, **P < 0.01), normalized to GAPDH. (B) Western blot analysis of Pax7,
myogenin, and follistatin expression in proliferating myoblasts following recombinant Wnt3a or control BSA protein treatments. (C) qPCR analysis
of myogenin expression in proliferating myoblasts following recombinant Wnt3a, Dkk1, or control BSA protein treatments. Data are presented as
the mean ± SEM (n = 3, **P < 0.01), normalized to GAPDH. (D) qPCR analysis of locus enrichment in chromatin immunoprecipitated with α-myogenin
or control IgG antibodies from proliferating myoblasts following recombinant Wnt3a or control BSA protein treatments. Data are presented as the
mean ± SEM (n = 3, **P < 0.01). (E) qPCR analysis of follistatin expression in myoblasts treated with siScr and BSA, siScr and Wnt3a, or siMyog and
Wnt3a. Data are presented as the mean ± SEM (n = 3, **P < 0.01), normalized to GAPDH.
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differentiation in vivo
To investigate the role of the Wnt-follistatin pathway in
muscle regeneration in vivo, we treated regenerating
muscle with a small molecule agonist of canonical Wnt
signalling (Figure 4A). Previous studies demonstrate that
Wnt proteins are secreted by the myofiber during
muscle regeneration [9,11,15]. To further examine Wnt/
β-catenin signalling during regeneration, we treated
regenerating TA muscle at 2 and 4 days following
cardiotoxin (CTX) injury with either DMSO vehicle
or BIO, a pharmacological inhibitor of GSK3β activity
[35]. By inhibiting GSK3β, we effectively activate thecanonical Wnt signalling pathway in satellite cells
during the core stages of muscle regeneration. Seven
days following injury, we harvested RNA from total
muscle tissue and examined gene expression profiles.
Consistent with our in vitro data, we observed an
overall increase in myogenin and follistatin expression, as
well as an increase in Myh2 (Figure 4B). These results
suggest that in vivo stimulation of β-catenin activity
promotes myogenic differentiation.
Following the direct delivery of the small molecule
Wnt agonist BIO, we observed altered muscle fiber
morphology (Figure 4C), resulting in an increased number
of fibers, as well as a dramatic reduction in cross-sectional
Figure 4 Canonical Wnt signalling promotes precocious differentiation in vivo. (A) Experimental time-course for in vivo muscle injury. Mice
undergo direct muscle injections of BIO 2 and 4 days post-CTX injury. (B) qPCR analysis of myogenin, follistatin, and Myh2 expression in TA muscle
7 days following CTX injury. Data are presented as the mean ± SEM (n = 3, **P < 0.01), normalized to GAPDH. (C) Representative cryosections of TA
muscle 7 days following CTX injury and treatment with GSK3β inhibitor (BIO) or DMSO control. Scale bar 50 μm. (D) Quantification of muscle fiber
caliber in TA muscles 7 days following CTX injury and BIO treatment. Data are presented as the mean ± SEM (n = 3, *P < 0.05).
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experiments examining Wnt stimulation in regenerating
muscle [9,11]. Furthermore, these results substantiate
our in vitro observations as treatment of regenerating
skeletal muscle with a canonical Wnt signalling agonist
reduces its regenerative potential through initiating
premature myogenic differentiation. Taken together,
these observations suggest canonical Wnt signalling
promotes differentiation by stimulating the expression
of myogenin and follistatin in vivo.Discussion
Canonical Wnt signalling is essential for proper myogenic
development and regeneration. However, in aged skel-
etal muscle, excessive Wnt/β-catenin signalling results
in precocious differentiation of satellite cells into the
fibroblast lineage, resulting in a depletion of the satellite
cell pool and inefficient muscle regeneration [11,14].
Furthermore, recent studies have shown that canon-
ical Wnt/β-catenin agonists promote myogenic differ-
entiation [36-38].
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cycle arrest and activation of myogenin - a core MRF
transcription factor responsible for fusion and terminal
differentiation (Figure 1). In situ analysis of satellite cells
on single myofibers identified an increase in the percentage
of satellite myogenic progenitors that express myogenin.
Following Wnt3a treatment myoblasts induced to differen-
tiate displayed enhanced fusion (Figure 2B,C), an effect lost
following Dkk1-mediated inhibition of endogenous Wnt
signalling. Endogenous Wnt3a expression is induced in
cultured myofibers, consistent with the observation that
Wnt expression is low during the early phase of regener-
ation when progenitor expansion is occurring, with a sub-
sequent increase to promote myogenic commitment and
differentiation [11,15,39]. Interestingly, recent research
suggests that it is not the initial activation of Wnt signal-
ling but rather it is inhibition following the expansion of
the satellite cell pool that is critical for proper adult skeletal
muscle regeneration [40].
Among the genes upregulated following Wnt3a stimula-
tion of proliferating myoblasts, the myogenic regulatory
factor myogenin plays a prominent role in regulating myo-
blast fusion and terminal differentiation. While myogenin
expression is normally upregulated during differentiation,
we observed a strong increase of myogenin protein
following Wnt3a stimulation (Figure 3B), a feature not
observed following non-canonical Wnt7a stimulation
(data not shown). This upregulation of myogenin may
serve as a node for the canonical Wnt-induced switch to
myogenic differentiation, regardless of the pro-proliferative
culture conditions. We previously observed that canonical
Wnt signalling reduced myoblast proliferation rate in vitro
[9], and these results are further explained taking into
account the activation of myogenin and the significant
repression of genes involved in cell cycle progression
(Figure 1C, Additional file 5: Table S2).
Myogenic differentiation is a highly orchestrated process,
with cell cycle withdrawal occurring before the expression
of contractile proteins or cell fusion [41,42]. Myogenin ex-
pression leads to the downregulation of genes involved in
cell cycle progression, and its expression is sufficient to
induce cell cycle withdrawal [32]. This indirect cell cycle re-
pression occurs via the myogenin-dependent expression of
miR-20a, a microRNA well characterized in its silencing of
E2F1 and E2F3 [43,44]. In addition, the induction of myo-
genin expression is dependent on tissue-specific expression
of MyoD, co-operating with ubiquitously expressed Six,
Mef2, and Pbx1 protein families and in concert with the
epigenetic modifications of chromatin structure [45]. While
Wnt3a treatment did not further induce MyoD expression
(data not shown), it should be noted that activated
myoblasts already express high levels of MyoD protein.
While its transcriptional activity is generally associated
with TCF/Lef proteins, recent studies are establishing apotential TCF/Lef-independent function of β-catenin. As
discussed, MyoD is able to complex with β-catenin
independent of E-proteins [33], whose interaction
preferentially binds muscle-specific E-box elements
and promotes myogenic differentiation. In addition to
MyoD, β-catenin has been described in regulating
TCF-independent transcription with Sox proteins [46],
FoxO proteins [47], homeodomain proteins Prop1
[48] and PitX2 [49], hypoxia-inducible factor 1α
(HIF1α) [50], and type I and type II nuclear receptors [51].
These findings further suggest that while the classical
TCF/Lef-dependent β-catenin transcriptional activation
remains important, a TCF/Lef-independent role for
β-catenin provides a previously uncharacterized level
of gene regulation.
Follistatin is a secreted glycoprotein that antagonizes
various members of the TGF-β superfamily, including
myostatin [52,53]. Originally identified in porcine ovarian
follicular fluid, follistatin was suggested to promote muscle
fiber hypertrophy by antagonizing the myostatin mediated
repressive effects on myogenic progenitor differentiation
and muscle fiber growth [29,30]. Through inhibiting myos-
tatin and activin A activity, follistatin overexpression leads
to a more dramatic muscle phenotype than the myostatin-
null mouse [31]. Strikingly, follistatin regulation remains
functional in myostatin-null mice, suggesting a myostatin-
independent function [54,55]. Recent observations suggest
that follistatin promotes muscle hypertrophy through
suppressing the phosphorylation of Smad3, resulting in
potentiation of mTOR/S6 protein kinase (S6K)/S6 riboso-
mal protein (S6RP) signalling and inhibition of GSK3β
[56,57]. The mTOR-dependent phosphorylation of S6RP
leads to increased protein synthesis and cell size from en-
hanced protein translation initiation and elongation [58].
In the absence of exogenous canonical Wnt stimulation,
myogenin is bound to the follistatin locus early during
differentiation and is presumably responsible for the rapid
follistatin expression observed following 24 h of myogenic
differentiation (Figure 1D). We previously found that the
Snail DNA-binding zinc finger transcriptional repressors
bind the same DNA motif as the bHLH transcription
factors MyoD and myogenin [28]. In proliferating myo-
blasts, Snail prevents MyoD occupancy on differentiation-
specific regulatory elements, and the change from Snail to
MyoD/myogenin binding often results in enhancer switch-
ing during differentiation and recruitment of histone
acetylase activity on the myogenin promoter.
Upon Wnt3a stimulation, we observe myogenin binding
to an E-box element not occupied during proliferation
conditions (Figure 3D, Additional file 2: Figure S1).
While TCF/Lef sites have been identified in the follis-
tatin promoter [59,60], our data suggests that myo-
genin is directly involved in regulating follistatin
transcription, through a regulatory E-box element, both
Jones et al. Skeletal Muscle  (2015) 5:14 Page 10 of 11during differentiation and following Wnt3a-induced pre-
cocious differentiation.
Following injury-induced regeneration, we observed
that treatment with a GSK3β antagonist further potentiated
the differentiation effects of canonical Wnt signalling
(Figure 4B,C). Specifically, further induction of myogenic
genes and follistatin expression induced rapid differenti-
ation of regenerating fibers, resulting in premature fusion
and production of an increased number of smaller fibers
(Figure 4C,D). The application of a pharmacological
antagonist, which replicates observations from plasmid
electroporation and protein injections, remains promising
as it provides efficient delivery and dispersion within
structured skeletal muscle.Conclusions
Canonical Wnt/β-catenin signalling promotes myogenic
differentiation. The mechanism by which this occurs was
previously thought to involve direct binding of β-catenin
to the follistatin promoter [36]. Our experiments suggest
a complementary pathway exists involving Wnt/β-catenin
induction of myogenin and its subsequent binding to and
activating the expression of follistatin. These results
provide a novel mechanistic framework that helps explain
how canonical Wnt/β-catenin signalling promotes early
myogenic differentiation.Additional files
Additional file 1: Table S1. Primer sequences used for gene-specific
mRNA quantitation by qPCR.
Additional file 2: Figure S1. Enriched gene ontology terms following
Wnt3a treatment. (A) Gene ontology terms enriched among upregulated
genes following Wnt3a stimulation for 24 h relative to BSA control. (B)
Gene ontology terms enriched among downregulated genes following
Wnt3a stimulation for 24 h relative to BSA control.
Additional file 3: Figure S2. Myogenin binding site upstream of the
follistatin locus. Myogenin peaks mapped to the UCSC genome browser,
with scale set to automatic. A myogenin bound motif 30-kb upstream of the
follistatin promoter is shown following induction of 2 days differentiation
(Rudnicki Lab, unpublished data).
Additional file 4: Figure S3. Wnt3a activates myogenin expression in
proliferating myoblasts myogenin expression levels analyzed by qPCR in
proliferating myoblasts treated for 24 h with siMyog and BSA, siScr and
Wnt3a, or siMyog and Wnt3a. Data are presented as the mean ± SEM
(n = 3, **P < 0.01), normalized to GAPDH.
Additional file 5: Table S2. Summary of Wnt3a regulated changes in
gene expression as assessed by Affymetrix microarray performed in
biological triplicate.Abbreviations
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